biostudies-literatureWard ZJNational Cancer InstituteNCI NIH HHSHarvard T.H. Chan School of Public Health341-350https://www.ebi.ac.uk/biostudies/studies/S-EPMC8033570biostudies-literatureUnknown22(3)<h4>Background</h4>In addition to increased availability of treatment modalities, advanced imaging modalities are increasingly recommended to improve global cancer care. However, estimates of the costs and benefits of investments to improve cancer survival are scarce, especially for low-income and middle-income countries (LMICs). In this analysis, we aimed to estimate the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival, both globally and by country income group.<h4>Methods</h4>Using a previously developed model of global cancer survival, we estimated stage-specific cancer survival and life-years gained (accounting for competing mortality) in 200 countries and territories for patients diagnosed with one of 11 cancers (The Lancet. OncologyGlobal costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.PMC8033570P30 CA008748Scott AMAtun RWard ZJHricak HfalseGlobal costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.<h4>Background</h4>In addition to increased availability of treatment modalities, advanced imaging modalities are increasingly recommended to improve global cancer care. However, estimates of the costs and benefits of investments to improve cancer survival are scarce, especially for low-income and middle-income countries (LMICs). In this analysis, we aimed to estimate the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival, both globally and by country income group.<h4>Methods</h4>Using a previously developed model of global cancer survival, we estimated stage-specific cancer survival and life-years gained (accounting for competing mortality) in 200 countries and territories for patients diagnosed with one of 11 cancers (2021-01-01T00:00:00Z2021 Mar2025-04-04T10:16:00.86Z2025-04-04T10:16:00.86ZS-EPMC80335703366228610.1016/s1470-2045(20)30750-610.1016/S1470-2045(20)30750-6